The pharmaceutical giants GlaxoSmithKline and Sanofi Pasteur have announced that they will supply the United States with 100 million doses of an experimental coronavirus vaccine as governments buy up supplies in hopes of securing a successful candidate.
The United States will spend up to $2.1 billion for the vaccine’s “production of clinical testing, processing, scale-up and distribution,” the two European-based firms said in a statement. Sanofi’s having the bulk of the money.
As part of the Operation High Speed plan, the U.S. government has another opportunity to include an extra 500 million doses in the longer term.
Attempts to create a coronavirus vaccine
“The portfolio of vaccines being assembled for Operation Warp Speed. It increases the odds that as soon as the end of this year we’ll have at least one safe , effective vaccine”. US. Alex Azar, the secretary of health and human services, also said in a statement.
The Uk government reached a contract earlier this week for 60 million doses of a new coronavirus vaccine that will begin to roll out in the first half of next year.
The vaccine developing by GSK from Britain and Sanofi’s from France is on existing DNA-based technology. Which means to produce the seasonal flu vaccine from Sanofi. It is one of the emerging vaccines.
“The worldwide need for a vaccine to help avoid COVID-19 is enormous. No one vaccine or organization can satisfy market demand alone”. Thomas Triomphe, Sanofi Pasteur’s executive vice-president said.
The European Union’s executive arm released a statement later Friday. It’s announcing it had ended exploratory talks with Sanofi to “include an opportunity. For all EU Member States to purchase the vaccine”. The aim should be to also provide a negotiated basis for purchasing 300 million doses should the vaccine function.
“We are also in early negotiations with a variety of other businesses,” said EU Commission Member Ursula von der Leyen.